Boston Scientific (BSX) Offering Possible 12.87% Return Over the Next 27 Calendar Days

Boston Scientific's most recent trend suggests a bullish bias. One trading opportunity on Boston Scientific is a Bull Put Spread using a strike $42.00 short put and a strike $37.00 long put offers a potential 12.87% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $42.00 by expiration. The full premium credit of $0.57 would be kept by the premium seller. The risk of $4.43 would be incurred if the stock dropped below the $37.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Boston Scientific is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Boston Scientific is bullish.

The RSI indicator is at 51.4 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Boston Scientific

10 Stable Growth Stocks That Are Still Worth the Price, According to an Analyst
Thu, 19 Sep 2019 13:35:00 +0000
What separates winners from losers, UBS strategist Francois Trahan said, is “beta”—a volatility metric measuring how much a stock deviates from the market’s movement. Think Facebook, Alphabet and Boston Scientific.

Boston Scientific Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2019
Wed, 18 Sep 2019 10:45:00 +0000
MARLBOROUGH, Mass. , Sept. 18, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT), …

BAX or BSX: Which Is the Better Value Stock Right Now?
Fri, 13 Sep 2019 13:40:01 +0000
BAX vs. BSX: Which Stock Is the Better Value Option?

IoMT Becomes the Buzzword in New Age MedTech Investing
Fri, 13 Sep 2019 13:13:01 +0000
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.

Morgan Stanley: Buy These 3 Stocks on Recent Weakness
Tue, 10 Sep 2019 15:07:35 +0000
Investors are always looking for stocks that represent compelling investment opportunities but finding them isn’t always an easy task. That being said, Wall Street’s top investment firms can provide helpful insights as to which stocks boast a strong long-term growth narrative. Top analysts from Morgan Stanley have released updates on a few stocks that do just that.The firm recently issued recommendations on 3 stocks, highlighting each as presenting a unique buying opportunity given recent weakness. Each boasts significant support from the rest of the Street as well as potential for substantial long-term upside.Bearing this in mind, we used TipRanks’ investing tools to take a closer look at Morgan Stanley’s 3 picks. Here’s what we found out. Uber Technologies Inc. (UBER)It’s no question that it has been a bumpy ride for Uber since going public. As of its May 10 IPO date, shares are down 20% with some investors expressing their concern that recent headwinds will further delay a turnaround.Uber has been bogged down by costs related to its public offering. On August 8, the company reported a second quarter loss of $5.2 billion, its largest ever quarterly loss, as a result of $3.9 billion worth of stock-based compensation expenses it incurred from the IPO. Even without those expenses, the ride sharing company still lost approximately $1.3 billion. However, management points out that its heavy investments in Uber Freight, food delivery and price reductions in its ride-hailing business can be attributed to the loss.New regulation in California also threatens to derail Uber’s plans to reach profitability. California senators will vote on Assembly Bill 5 (AB5) this month which if passed, would make it more difficult for gig economy companies to classify workers as independent contractors. This would force Uber to consider drivers employees, which would adversely affect business.That being said, Uber could pass the added costs along to consumers in order to offset some of the impacts of AB5. Not to mention the company stated on September 6 that it plans to invest $200 million per year in its fasting growing segment, Uber Freight. One top analyst, Brian Nowak, argues that Uber has multiple ways to offset the headwind of AB5 being approved. “We expect Uber to pass through most of the higher costs to consumers and minimize the cash flow headwind…balancing the incremental costs Uber will bear with the expected impact on consumer demand from higher fares. This will come at a cost with an estimated 2021 negative financial impact ranging from 6-16% of contribution profit,” he explained. As a result, the five-star analyst reiterated his Buy rating and $57 price target on September 5. He thinks shares have the potential to surge 59% in the next twelve months.All in all, Wall Street is bullish on the ride sharing platform. Uber boasts a ‘Strong Buy’ analyst consensus and a $54 average price target, indicating 61% upside potential. Domino's Pizza, Inc. (DPZ)While the pizza delivery chain hasn’t been shy about acknowledging the threat of third-party delivery services in recent quarters, Morgan Stanley tells investors to keep putting DPZ on their plates even though shares have dropped 1% year-to-date. Domino’s Pizza invited several Wall Street analysts including Morgan Stanley’s John Glass to its “innovation garage” on September 6. The event showcased its new innovation and technology initiatives, with the analyst telling investors he remains convinced the company is set to serve up long-term gains.While DPZ didn’t actually reveal anything brand new at the event, it did go a long way to renew the analyst’s confidence in the pizza chain. Among his takeaways from the event, Glass highlighted the fact that management maintained that it will be able to meet its three to five year same store sales guidance of 3% to 6% growth. Domino’s expects to achieve this thanks to several of its near-term initiatives. As part of these initiatives, DPZ will start offering better carryout options as well as 20% off all orders placed after 9 p.m. Adding to the good news, its GPS tracking is expected to be launched systemwide by the end of 2019. The company will also start testing autonomous vehicles to provide a cheaper delivery option for customers as they won’t need to tip. Glass sees all of the above as steps in the right direction. “Unlike a typical analyst meeting, this event didn't break new news, but what we did hear was generally positive as management outlined some more specific near-term steps to drive domestic sales,” he explained. As a result, the four-star analyst reiterated his Buy rating and $287 price target on September 9. The price target demonstrates Glass’ confidence in DPZ’s ability to gain 17% over the next twelve months.With 14 Buy ratings vs 7 Holds and 1 Sell assigned over the last three months, the word on the Street is that DPZ is a ‘Moderate Buy’. Its $285 average price target suggests 16% upside potential. Boston Scientific Corporation (BSX)The last stock on our list manufactures medical devices designed to provide less invasive medical solutions. Its devices include defibrillators, pacemakers as well as many other products for interventional medical specialties. While shares have declined 0.14% in the last month, Morgan Stanley’s David Lewis tells investors BSX shares are poised for long-term gains.According to BSX’s July 24 Q2 earnings release, the company looks solid. It generated quarterly sales of $2.6 billion, up 5.6% on a reported basis and 6.3% on an organic basis from the year-ago quarter. Management attributes this to revenue growth across all segments.The company’s latest acquisitions and new products are expected to drive even more growth. On August 26, BSX finalized its $4.2 billion acquisition of BTG plc, helping BSX expand its interventional oncology, arterial and venous therapy product offerings. It also acquired Vertiflex Inc. back in June, which designed a minimally-invasive device to improve physical function and reduce pain in patients with lumbar spinal stenosis, or the narrowing of the spinal canal.Not to mention BSX announced the FDA approval for its ImageReady MRI labeling for the Vercise Gevia Deep Brain Stimulation (DBS) system in an MRI environment on August 19. The system, along with the Vercise Cartesia Directional Lead, was developed to treat symptoms of Parkinson’s Disease, a progressive nervous system disorder that can cause shaking, muscle stiffness and slow movement. It’s estimated that 10 million people are affected by the debilitating disease globally.All of these positive developments contributed to Lewis’ conclusion that BSX’s long-term growth narrative remains strong. As a result, he reiterated his Buy rating and $50 price target on August 29. The four-star analyst sees 20% upside potential for the company. All in all, the rest of the Street mirrors the analyst’s sentiment. Boston Scientific boasts a ‘Strong Buy’ Street consensus as well as a $49 average price target, implying 16% upside potential. Discover the Street’s best-rated stocks with the Top Analysts’ Stocks tool

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.